指南与共识类风湿关节炎

EULAR 难治性类风湿关节炎管理要点

EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis.
指南 / 共识 · Ann Rheum Dis · 2021-08-18

EULAR 工作组基于两项系统文献综述制定难治性类风湿关节炎(D2T RA)管理要点,涵盖诊断确认、炎症活动评估、药物与非药物干预、治疗依从性、功能障碍、疼痛、疲劳、目标设定、自我效能及合并症影响,共2项总体原则和11条要点,推荐强度C-D,平均同意度8.4-9.6,高质量证据稀缺。

要点

  • D2T RA管理需综合评估诊断确认、炎症活动及合并症。
  • 推荐涵盖药物与非药物干预、依从性、功能、疼痛和疲劳。
  • 推荐强度C-D,平均同意度高(8.4-9.6),高质量证据少。

核心结论

  • 这些D2T RA管理要点可作为临床路线图,支持医护人员和患者实施整体管理及更个性化的药物与非药物治疗策略。
  • 高质量证据稀缺,已创建研究议程以指导未来研究。

研究设计与样本

  • EULAR工作组由34人组成:26名风湿科医生、患者伙伴及有风湿病经验的专业卫生人员。
  • 两项系统文献综述围绕D2T RA的诊断挑战及药物和非药物治疗策略的临床问题。

主要发现

  • 定义了2项总体原则和11条要点,涉及RA诊断确认、炎症活动评估、药物与非药物干预、治疗依从性、功能障碍、疼痛、疲劳、目标设定、自我效能及合并症影响。
  • 推荐强度从C级到D级不等。
  • 对总体原则和要点的平均同意度普遍较高(8.4-9.6)。

关键数值与推荐

  • 推荐强度量表A-D:A通常为一致的一级研究,D为五级证据或不一致研究。
  • 同意度量表0-10:0完全不同意,10完全同意。
  • 平均同意度范围为8.4-9.6。

临床怎么用

  • 作为临床路线图,支持医护人员和患者实施D2T RA的整体管理。
  • 指导制定更个性化的药物和非药物治疗策略。

局限性

  • 高质量证据稀缺。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To develop evidence-based European Alliance of Associations for Rheumatology (EULAR) points to consider (PtCs) for the management of difficult-to-treat rheumatoid arthritis (D2T RA). METHODS: An EULAR Task Force was established comprising 34 individuals: 26 rheumatologists, patient partners and rheumatology experienced health professionals. Two systematic literature reviews addressed clinical questions around diagnostic challenges, and pharmacological and non-pharmacological therapeutic strategies in D2T RA. PtCs were formulated based on the identified evidence and expert opinion. Strength of recommendations (SoR, scale A-D: A typically consistent level 1 studies and D level 5 evidence or inconsistent studies) and level of agreement (LoA, scale 0-10: 0 completely disagree and 10 completely agree) of the PtCs were determined by the Task Force members. RESULTS: Two overarching principles and 11 PtCs were defined concerning diagnostic confirmation of RA, evaluation of inflammatory disease activity, pharmacological and non-pharmacological interventions, treatment adherence, functional disability, pain, fatigue, goal setting and self-efficacy and the impact of comorbidities. The SoR varied from level C to level D. The mean LoA with the overarching principles and PtCs was generally high (8.4-9.6). CONCLUSIONS: These PtCs for D2T RA can serve as a clinical roadmap to support healthcare professionals and patients to deliver holistic management and more personalised pharmacological and non-pharmacological therapeutic strategies. High-quality evidence was scarce. A research agenda was created to guide future research.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Nagy G, Roodenrijs NMT, Welsing PMJ, et al. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021. PMID: 34407926. doi:10.1136/annrheumdis-2021-220973

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。